Abstract:Cystic fibrosis (CF) is a fatal autosomal recessive disorder caused by the loss of function mutations within a single gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). CFTR is a chloride channel that regulates ion and fluid transport across various epithelia. The discovery of CFTR as the CF gene and its cloning in 1989, coupled with extensive research that went into the understanding of the underlying biological mechanisms of CF, have led to the development of revolutionary therapies in CF that we see today. The highly effective modulator therapies have increased the survival rates of CF patients and shifted the epidemiological landscape and disease prognosis. However, the differential effect of modulators among CF patients and the presence of non-responders and ineligible patients underscore the need to develop specialized and customized therapies for a significant number of patients. Recent advances in the understanding of the CFTR structure, its expression, and defined cellular compositions will aid in developing more precise therapies. As the lifespan of CF patients continues to increase, it is becoming critical to clinically address the extra-pulmonary manifestations of CF disease to improve the quality of life of the patients. In-depth analysis of the molecular signature of different CF organs at the transcriptional and post-transcriptional levels is rapidly advancing and will help address the etiological causes and variability of CF among patients and develop precision medicine in CF. In this review, we will provide an overview of CF disease, leading to the discovery and characterization of CFTR and the development of CFTR modulators. The later sections of the review will delve into the key findings derived from single-molecule and single-cell-level analyses of CFTR, followed by an exploration of disease-relevant protein complexes of CFTR that may ultimately define the etiological course of CF disease.

Precision medicine advances in cystic fibrosis: Exploring genetic pathways for targeted therapies

Cystic fibrosis management in pediatric population—from clinical features to personalized therapy

Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians

Advances in the Cystic Fibrosis Drug Development Pipeline

Current landscape of cystic fibrosis gene therapy

Future therapies for cystic fibrosis

Cystic Fibrosis: A Journey through Time and Hope

Functional Consequences of CFTR Interactions in Cystic Fibrosis

Gene therapy for cystic fibrosis: Challenges and prospects

Gene Therapy for Cystic Fibrosis Lung Disease: Overcoming the Barriers to Translation to the Clinic

New drugs, new challenges in cystic fibrosis care

[Therapeutics in cystic fibrosis: Clinical revolution and new challenges]

Ion Channel Modulators in Cystic Fibrosis

A new era of targeting cystic fibrosis with non-viral delivery of genomic medicines

Genetic medicines for CF: Hype versus reality

Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy

Genetic Modifying Factors of Cystic Fibrosis Phenotype: A Challenge for Modern Medicine

An Update on CFTR Modulators as New Therapies for Cystic Fibrosis

The future of cystic fibrosis: A global perspective

Impact of Gene Modifiers on Cystic Fibrosis Phenotypic Profiles: A Systematic Review

Update on new pulmonary therapies